Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 June 2019Website:
http://www.artelobio.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
pre-market | 12 min agoDividend
Analysts recommendations
Institutional Ownership
ARTL Latest News
Multiple studies confirm ART12.11's superior advantages as a product candidate for the treatment of anxiety related disorders Multiple studies confirm ART12.11's superior advantages as a product candidate for the treatment of anxiety related disorders
New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathy New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathy
ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD
What type of business is Artelo Biosciences?
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
What sector is Artelo Biosciences in?
Artelo Biosciences is in the Healthcare sector
What industry is Artelo Biosciences in?
Artelo Biosciences is in the Biotechnology industry
What country is Artelo Biosciences from?
Artelo Biosciences is headquartered in United States
When did Artelo Biosciences go public?
Artelo Biosciences initial public offering (IPO) was on 21 June 2019
What is Artelo Biosciences website?
https://www.artelobio.com
Is Artelo Biosciences in the S&P 500?
No, Artelo Biosciences is not included in the S&P 500 index
Is Artelo Biosciences in the NASDAQ 100?
No, Artelo Biosciences is not included in the NASDAQ 100 index
Is Artelo Biosciences in the Dow Jones?
No, Artelo Biosciences is not included in the Dow Jones index
When does Artelo Biosciences report earnings?
Next earnings report date is not announced yet